4DMedical Ltd
ASX:4DX
Intrinsic Value
4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. [ Read More ]
The intrinsic value of one 4DX stock under the Base Case scenario is 0.48 AUD. Compared to the current market price of 0.6 AUD, 4DMedical Ltd is Overvalued by 20%.
Valuation Backtest
4DMedical Ltd
Run backtest to discover the historical profit from buying and selling 4DX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
4DMedical Ltd
Current Assets | 61.7m |
Cash & Short-Term Investments | 47.9m |
Receivables | 10.3m |
Other Current Assets | 3.4m |
Non-Current Assets | 82.1m |
PP&E | 8.4m |
Intangibles | 73.6m |
Other Non-Current Assets | 44.8k |
Current Liabilities | 33.9m |
Accounts Payable | 7.3m |
Accrued Liabilities | 1.5m |
Other Current Liabilities | 25.1m |
Non-Current Liabilities | 18.7m |
Long-Term Debt | 3.9m |
Other Non-Current Liabilities | 14.8m |
Earnings Waterfall
4DMedical Ltd
Revenue
|
1m
AUD
|
Cost of Revenue
|
-51.3k
AUD
|
Gross Profit
|
973.9k
AUD
|
Operating Expenses
|
-32.6m
AUD
|
Operating Income
|
-31.6m
AUD
|
Other Expenses
|
803.3k
AUD
|
Net Income
|
-30.8m
AUD
|
Free Cash Flow Analysis
4DMedical Ltd
4DX Profitability Score
Profitability Due Diligence
4DMedical Ltd's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
4DMedical Ltd's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
4DX Solvency Score
Solvency Due Diligence
4DMedical Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
4DMedical Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
4DX Price Targets Summary
4DMedical Ltd
According to Wall Street analysts, the average 1-year price target for 4DX is 1.16 AUD with a low forecast of 1.11 AUD and a high forecast of 1.26 AUD.
Shareholder Return
4DX Price
4DMedical Ltd
Average Annual Return | -20.87% |
Standard Deviation of Annual Returns | 65.47% |
Max Drawdown | -89% |
Market Capitalization | 234.5m AUD |
Shares Outstanding | 391 375 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-08-07. The firm is focused on development of a non-invasive respiratory imaging solution using four-dimensional imaging. The firm's XV Technology is a four-dimensional lung imaging technology that utilizes mathematical models and algorithms to convert X-ray scans into quantitative data for physicians to manage patients with respiratory diseases and diseases of the lung. The XV Technology is accessible through a cloud-based software as a service (SaaS) platform that integrates with existing hospital equipment. The XV Technology Lung Ventilation Analysis Software (XV LVAS Ventilation) provides a non-invasive way of understanding regional lung motion and airflow. The company enables physicians to detect areas of high and low ventilation from all parts of the lung, in all phases of the breath.
Contact
IPO
Employees
Officers
The intrinsic value of one 4DX stock under the Base Case scenario is 0.48 AUD.
Compared to the current market price of 0.6 AUD, 4DMedical Ltd is Overvalued by 20%.